Shanghai Fosun Pharmaceutical (600196.SH): The Phase I/II clinical trial of HLX701 in combination with cetuximab and chemotherapy for the treatment of advanced colorectal cancer has been approved.

Shanghai Fosun Pharmaceutical (600196.SH) announced recently that its controlling subsidiary, Shanghai HENLIUS Biotechnology Co., Ltd., and its subsidiaries (hereinafter referred to as "HENLIUS"), have received approval from the National Medical Products Administration to conduct Phase Ib/II clinical trials of HLX701 (recombinant human SIRP-IgG4 Fc fusion protein injection) in combination with cetuximab and chemotherapy for the treatment of advanced colorectal cancer. HENLIUS plans to conduct relevant clinical trials of this drug in China (excluding Hong Kong, Macau, and Taiwan). HLX701 was licensed by HENLIUS in June 2025 from FBD Biologics Limited and granted exclusive regional licenses for development, production, and commercialization in the region (including mainland China, Hong Kong, Macau, agreed Southeast Asian countries, the Middle East, and North Africa). As of the date of this announcement (January 20, 2026), there are no approved CD47-targeted SIRP-Fc fusion proteins on the market worldwide.